Sex differences in flow cytometry–based platelet reactivity in stable outpatients suspected of myocardial ischemia

Autor: Diederick E. Grobbee, Leo Timmers, Dominique P.V. de Kleijn, Ingrid E.M. Bank, A. Mosterd, Mirthe Dekker, Gert J. de Borst, Rolf T. Urbanus, Suzanne J.A. Korporaal, Farahnaz Waissi, Asbjørn M. Scholtens, Gerard Pasterkamp
Přispěvatelé: Graduate School, ACS - Heart failure & arrhythmias
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 5, Pp 879-885 (2020)
Research and Practice in Thrombosis and Haemostasis
Research and practice in thrombosis and haemostasis, 4(5), 879-885. Wiley-Blackwell Publishing Ltd
ISSN: 2475-0379
Popis: Background Antiplatelet therapy is the mainstay of secondary prevention of cardiovascular events. Studies suggest that women do not obtain equal therapeutic benefit from antiplatelet therapy compared with men. The link between sex differences in platelet biology and response to antiplatelet therapies is unclear. We therefore investigated the role of sex differences in platelet reactivity in a cohort of outpatients with chest pain, in response to treatment with antiplatelet agents. Methods Platelet reactivity was measured in 382 randomly selected patients participating in the Myocardial Ischemia Detection by Circulating Biomarkers (MYOMARKER) study, an observational cohort study of outpatients suspected of myocardial ischemia. In all patients, blood was collected during diagnostic workup, and platelet reactivity was assessed with a flow cytometry–based platelet activation test that quantifies both platelet degranulation (P‐selectin expression) and platelet aggregation (fibrinogen binding to integrin αIIbβ3) in whole blood. Results Platelet reactivity was higher in women compared with men when activated with protease activating receptor 1–activating peptide SFLLRN (PAR1‐AP) and adenosine 5′‐phosphate (ADP), independent of age, basal activation status, estimated glomerular filtration rate
Databáze: OpenAIRE